Literature DB >> 26833174

Hippocampal dysfunction defines disease onset in Huntington's disease.

Faye Begeti1, Laetitia C Schwab1, Sarah L Mason1, Roger A Barker2.   

Abstract

BACKGROUND: Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder characterised by a triad of motor, psychiatric and cognitive deficits with the latter classically attributed to disruption of frontostriatal networks. However, emerging evidence from animal models of HD suggests that some of the early cognitive deficits may have a hippocampal basis. The objective of this study was to link previous rodent findings in this area to clinical practice.
METHODS: In this study, 94 participants included patients with early HD, premanifest HD and age-matched controls underwent hippocampal-based cognitive assessments. These included a virtual reality version of the Morris water maze, a task involved participants having to swim through a virtual pool to find a submerged platform using a joystick, and the Cambridge Neuropsychological Test Automated Battery (CANTAB) paired associates learning task, a test also known to rely on hippocampal integrity.
RESULTS: Patients with early HD showed impaired performance in both the virtual Morris water maze and the CANTAB paired associates learning. Such deficits were also correlated with estimated years to diagnosis in premanifest participants.
CONCLUSIONS: This study highlights the merit of using analogous tests in the laboratory and clinic and demonstrates that hippocampal impairments are an early feature of HD in patients as previously shown in rodent models of the disease. As such, they could be used not only to assist in the diagnosis of disease onset, but may also be useful as an outcome measure in future therapeutic trials. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Mesh:

Year:  2016        PMID: 26833174     DOI: 10.1136/jnnp-2015-312413

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  16 in total

Review 1.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-24       Impact factor: 3.575

2.  Hippocampal Egr1-Dependent Neuronal Ensembles Negatively Regulate Motor Learning.

Authors:  Verónica Brito; Enrica Montalban; Anna Sancho-Balsells; Anika Pupak; Francesca Flotta; Mercè Masana; Silvia Ginés; Jordi Alberch; Claire Martin; Jean-Antoine Girault; Albert Giralt
Journal:  J Neurosci       Date:  2022-05-24       Impact factor: 6.709

3.  Altered m6A RNA methylation contributes to hippocampal memory deficits in Huntington's disease mice.

Authors:  Silvia Ginés; Verónica Brito; Anika Pupak; Ankita Singh; Anna Sancho-Balsells; Rafael Alcalá-Vida; Marc Espina; Albert Giralt; Eulàlia Martí; Ulf Andersson Vang Ørom
Journal:  Cell Mol Life Sci       Date:  2022-07-11       Impact factor: 9.207

4.  FGF2 and dual agonist of NCAM and FGF receptor 1, Enreptin, rescue neurite outgrowth loss in hippocampal neurons expressing mutated huntingtin proteins.

Authors:  Mirolyuba Ilieva; Troels T Nielsen; Tanja Michel; Stanislava Pankratova
Journal:  J Neural Transm (Vienna)       Date:  2019-09-09       Impact factor: 3.575

5.  Mutant Huntingtin Causes a Selective Decrease in the Expression of Synaptic Vesicle Protein 2C.

Authors:  Chaohua Peng; Gaochun Zhu; Xiangqian Liu; He Li
Journal:  Neurosci Bull       Date:  2018-04-30       Impact factor: 5.203

6.  Reduced expression of dopamine D2 receptors on astrocytes in R6/1 HD mice and HD post-mortem tissue.

Authors:  Kate L Harris; Sarah L Mason; Benjamin Vallin; Roger A Barker
Journal:  Neurosci Lett       Date:  2021-10-09       Impact factor: 3.197

7.  GSK-3β-induced Tau pathology drives hippocampal neuronal cell death in Huntington's disease: involvement of astrocyte-neuron interactions.

Authors:  F L'Episcopo; J Drouin-Ouellet; C Tirolo; A Pulvirenti; R Giugno; N Testa; S Caniglia; M F Serapide; G Cisbani; R A Barker; F Cicchetti; B Marchetti
Journal:  Cell Death Dis       Date:  2016-04-28       Impact factor: 8.469

8.  A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.

Authors:  Nuria Suelves; Lucy Kirkham-McCarthy; Robert S Lahue; Silvia Ginés
Journal:  Sci Rep       Date:  2017-07-20       Impact factor: 4.379

9.  Restoring GABAergic inhibition rescues memory deficits in a Huntington's disease mouse model.

Authors:  Zahra Dargaei; Jee Yoon Bang; Vivek Mahadevan; C Sahara Khademullah; Simon Bedard; Gustavo Morrone Parfitt; Jun Chul Kim; Melanie A Woodin
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-30       Impact factor: 11.205

10.  Impaired Performance of the Q175 Mouse Model of Huntington's Disease in the Touch Screen Paired Associates Learning Task.

Authors:  Tuukka O Piiponniemi; Teija Parkkari; Taneli Heikkinen; Jukka Puoliväli; Larry C Park; Roger Cachope; Maksym V Kopanitsa
Journal:  Front Behav Neurosci       Date:  2018-10-02       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.